MAIA Biotechnology, Inc. (MAIA)
NYSE American · Healthcare · Biotechnology
$1.18−0.84%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $72.9M
- Forward P/E
- 1.1
- 52-week range
- $0.87 – $3.19
- 52-week change
- −31.21%
- EPS (trailing)
- −$0.62
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Net income
- −$22.4M
- Diluted EPS
- −$0.70
From the company’s annual report on SEC EDGAR.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Headquarters: Chicago, United States · 13 employees · maiabiotech.com